| Pegasys (pegylated interferon α -2a) / Roche |
ACTRN12608000400369: A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre. |
|
|
| Recruiting | 4 | 50 | | | Dr Joe Sasadeusz, Roche Products Pty Ltd | Impact of standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection on: (i) quality of life, (ii) mental health status, (iii) injecting drug behaviours, and (iv) opioid pharmacotherapy use in active injecting drug users (IDUs)., Side effects related to chronic Hepatitis C virus (HCV) infection and treatment in active injecting drug users (IDUs)., Factors affecting compliance of active injecting drug users (IDUs) for standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection., Chronic hepatitis C virus (HCV) infection. | | | | |
ChiCTR-ONRC-05000623: Treatment with Peginterferon Alfa-2a (40 KD) (PEGASYS?) of Chronic Hepatitis B Patients, Who Have Failed Anti-Viral Treatment? A Pilot Study |
|
|
| Completed | 4 | 98 | | Peginterferon Alfa-2a (40 KD) (PEGASYS?) 180 mcq per week for 48 weeks versus placebo ;Peginterferon Alfa-2a (40 KD) (PEGASYS?) 180 mcq per week for 48 weeks versus placebo | Roche Hong Kong Limited; Level of the institution：, Hepatitis Research Fund | Viral Diseases | | | | |
ChiCTR-TRC-10000770: Research of Combination Therapy of Western and Traditional Chinese Medicine on Chronic Hepatitis C |
|
|
| Completed | 4 | 740 | | Binggan Granule 1, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 2, 1# bid for 12 months ;Binggan Granule 2, 1# bid for 12 months ;Pegasys 180ug qw+Ribavirin 300mg tid+Binggan Granule 1, 1# bid for 12 months | Shuguang Hospital Affiliated to Shanghai Univercity of Traditional Chinese Medicine; Level of the institution：, Ministry of Health, China | Chronic hepatitis C | | | | |
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | Chonic hepatitis HCV-related | | | | |
NCT01006512: Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma |
|
|
| Recruiting | 4 | 120 | RoW | Peginterferon alfa-2a plus ribavirin, pegasys | Kaohsiung Medical University | Chronic Hepatitis C, Neoplasms | 06/11 | 06/11 | | |
ChiCTR-TRC-10000926: A phase IV study on optimizing Pegasys plus Ribavirin treatment in difficult-to-treat Chronic Hepatitis C treatment naive patients. |
|
|
| Completed | 4 | 440 | | The subjects who meet EVR will be treated as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 48 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 72 weeks. ;The rest patients who fail to reach EVR will be randomized (1:1) into 2 study arms as follows: Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for totally 96 weeks | Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control | chronic hepatitis C | | | | |
ChiCTR-TRC-10000915: A phase IV study on optimizing Pegasys plus Ribavirin in the treatment of non-respond Chronic Hepatitis C patients |
|
|
| Completed | 4 | 100 | | Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks ;Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 96 weeks | Peking University People's Hospital; Ministry of Health, National S&T Major Project for Infectious Diseases Control | chronic hepatitis C | | | | |
ChiCTR-TRC-10000916: A phase IV study on optimizing Pegasys plus Ribavirin for paitents with relapse chronic Hepatitis C |
|
|
| Completed | 4 | 132 | | Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 48 weeks ;Pegasys 180μg/wk plus Ribavirin 10.6-15mg/kg/day for 72 weeks | Peking University People's Hospital; Ministry of Health, National S&T Key Project for Infectious Diseases Control | Chronic hepatitis C | | | | |
ChiCTR-RNRC-10001089: A study on optimizing Pegasys or Peg IFN alpha-2b plus Ribavirin in the treatment of non-responsive Chronic Hepatitis C patients |
|
|
| Completed | 4 | 100 | | Peg IFN alpha-2a is replaced by Peg IFNalpha-2b, Peg IFN alpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a is replaced by PegIFNalpha-2b: PegIFNalpha-2b 1.0-1.5ug/kg/wk plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks. Stop the medication if serum HCV RNA does not turn negative | 3rd Hospital of HeiBei Medical University; Level of the institution：, Hebei Science and Technology Bureau | chronic hepatitis C | | | | |
ChiCTR-TRC-09000612: Efficacy and safety of Pegasys combined with adefovir in the treatment of chronic hepatitis B with HBeAg(+) |
|
|
| Completed | 4 | 120 | | Pegasys ;Pegasys combined with adefovir | Third Hospital Affiliated to Zhongshan University; Level of the institution：, Self-financing | Chronic hepatitis B with HBeAg(+). | | | | |
ChiCTR-TRC-10001107: A phase IV study on optimizing Pegasys or Recombinant Human Interferonα2a pius Ribavirin for patients with relapse chronic Hepatitis C |
|
|
| Completed | 4 | 132 | | PegIFN alpha-2a changed with Peg IFN alpha-2b , PegIFN alpha-2b 1.0-1.5ug/kg/wk, plus Ribavirin 10.6-15mg/kg/day for 44 weeks after serum HCV RNA negative during 72-96 weeks ;PegIFN alpha-2a changed with PegIFN alpha-2b, PegIFN alpha-2b 1.0-1.5ug/kg/wk, plus Ribavirin 10.6-15mg/kg/day for 72-96 weeks without serum HCV RNA negative, then, PegIFN alpha-2b and Ribavirin were stopped | The Third Hospital of Hebei Medical University; Hebei Science and Technology Bureau, Hebei Science and Technology Bureau | chronic hepatitis C | | | | |
ChiCTR-TRC-10001090: A study on optimizing Pegasys or Recombinant Human Interferon α-2b plus Ribavirin in treatment of na?ve patients with chronic hepatitis C. |
|
|
| Completed | 4 | 260 | | The subjects will be treated as follows: Pegasys 180ug/wk plus Ribavirin 10.6-15mg/kg/day for 44 weeks after HCV RNA undetectable/clearance ;The rest patients will be treated as follows: IFNα-2b 500MU/2 days plus Ribavirin 10.6-15mg/kg/day for 44 weeks after HCV RNA undetectable /clearance | Third Hospital of HeiBei Medical University; Hebei Science and Technology Bureau, Hebei Science and Technology Bureau | chronic hepatitis C | | | | |
2014-005388-34: Single arm prospective clinical study to evaluate the efficacy of combination therapy sofosbuvir+ribavirin+peg-interferon in experienced patients with HCV-GT1 Studio clinico prospettico a braccio singolo di fase IV per la valutazione dell’efficacia e della sicurezza della terapia combinata Sofosbuvir + Ribavirina + Interferone Peghilato in pazienti con epatite cronica da HCV GT1 che hanno già fallito un precedente ciclo di duplice terapia con Ribavirina + Interferone Peghilato |
|
|
| Ongoing | 4 | 120 | Europe | SOVALDI, PEGASYS, RIBAVIRINA, 34459014, Film-coated tablet, Solution for injection, Capsule, hard, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 12 PENNE PRERIEMPITE, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER | AZIENDA OSPEDALIERA DI PADOVA, GILEAD SCIENCE S.R.L. - Italia | chronic hepatitis HCV GT1 who have already failed a prior course of dual therapy with pegylated interferon + ribavirin epatite cronica da HCV GT1 che hanno già fallito un precedente ciclo di duplice terapia con Ribavirina + Interferone Peghilato, chronic hepatitis HCV GT1 already treated epatite cronica da HCV GT1 già trattati, Diseases [C] - Virus Diseases [C02] | | | | |
2015-003024-31: Protecting immune responses in patients treated with the new DAA anti hepatitis C alone or in combination with previously used medications (interferon and ribavirin) Risposte immunitarie proteggenti in pazienti trattati con i nuovi farmaci anti epatite C (nuovi DAA) da soli o in associazione con i farmaci precedentemente utilizzati (interferone e ribavirina) |
|
|
| Not yet recruiting | 4 | 30 | Europe | PEGINTERFERONE ALFA-2A, RIBAVIRINA, SOFOSBUVIR, LEDIPASVIR+SOFOSBUVIR, N.A., Solution for injection, Capsule, hard, Film-coated tablet, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 1 PENNA PRERIEMPITA, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM | AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA, GILEAD SCIENCES SRL | CHRONIC HEPATITIS C EPATITE C CRONICA, CHRONIC HEPATITIS C EPATITE C CRONICA, Diseases [C] - Virus Diseases [C02] | | | | |
2005-002452-17: Pilot, open, multicenter, phase IV Clinical Trial to evaluate safety and efficacy in treatment with peginterferon alfa-2a plus ribavirin in VIH patients with advanced immunosupression and chronic hepatopathy secondary to hepatitis C virus. |
|
|
| Ongoing | 4 | 30 | Europe | peginterferon alfa 2a, ribavirin, peginterferon alfa 2a, ribavirin, Pegasys 180 microgrames, Pegasys 135 microgrames, Copegus 200 mg, Pegasys 180 microgrames, Pegasys 135 microgrames, Copegus 200 mg | Hospital Universitario de Valme | ¨Hepatitis C Crónica | | | | |
2005-005650-41: A Comparative, Randomized, Open-label, Multicenter Study, of Directly Observed Treatment of Chronic Hepatitis C (DOT) and auto administrated treatment with Copegus® (Ro 20-9963) and Pegasys® (Ro 25-8310). |
|
|
| Ongoing | 4 | 156 | Europe | Pegasys, Copegus, Ro 25-8310, Ro 20-9963, Pegasys, Copegus, Pegasys, Copegus | SESP | Chronic Hepatitis C | | | | |
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients |
|
|
| Ongoing | 4 | 230 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Miguel Santin Cerezales | Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels | | | | |
2007-002743-24: Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic patients |
|
|
| Ongoing | 4 | 140 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Queen Mary University of London | Chronic hepatitis C infection with genotype 3 and advanced fibrosis | | | | |
| Ongoing | 4 | 100 | Europe | Pegasys, Copegus, Ro25-8310/V01, R20-9963/J10, Pegasys, Copegus, Pegasys, Copegus | Västra Götalandsregionen | Chronic infection with hepatitis C virus, genotype 1, with signs of liver inflammation. | | | | |
2007-007075-16: The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - |
|
|
| Ongoing | 4 | 50 | Europe | Copegus, Actos, Pegasys, Actos, Pegasys | VU university medical center | Chronic hepatitis C infection | | | | |
2009-012459-96: VALORACIÓN INTENSIVA DE LA CINÉTICA DEL RNA DEL VIRUS DE LA HEPATITIS C COMO PREDICTOR PRECOZ DE AUSENCIA DE RESPUESTA VIROLÓGICA SOSTENIDA EN PACIENTES CON HEPATITIS CRÓNICA POR VHC TRATADOS CON INTERFERON PEGILADO Y RIBAVIRINA |
|
|
| Ongoing | 4 | 100 | Europe | pegintron, ribavirina, PEGASYS, 180 microgramos, solución inyectable en jeringa precargada, PEGINTRON 150 microgramos polvo y disolvente para solución inyectable en pluma precargada, REBETOL 200 mg cápsulas duras, PEGASYS, 180 microgramos, solución inyectable en jeringa precargada, PEGINTRON 150 microgramos polvo y disolvente para solución inyectable en pluma precargada, REBETOL 200 mg cápsulas duras | Dr Calleja Panero | HEPATITIS C | | | | |
ChiCTR-PPC-15006199: A Multi-center, Randomized, Controlled Clinical Trial of Pegylated interferon alpha-2a (40KD) Plus Ribavirin With or Without Vitamin D in Chronic Hepatitis C |
|
|
| Not yet recruiting | 4 | 224 | | vitamin D supplementation with pegylated interferon + ribavirin (PegIFN/RBV) ;pegylated interferon + ribavirin (PegIFN/RBV) | The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, Switzerland's Roche | Chronic hepatitis C | | | | |
NCT03013556: Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 180 | RoW | Group A, TDF, tenofovir, Group B:TDF then TDF and Peginterferon alfa-2a, tenofovir,pegasys, Group C:TDF and Peginterferon alfa-2a then TDF | Ruijin Hospital | Chronic Hepatitis | 12/21 | 12/21 | | |
NCT03084250: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC |
|
|
| Active, not recruiting | 4 | 150 | RoW | Peginterferon Alfa-2A, Pegasys, Adefovir, entecavir,tenofovir, either of them | Shanghai Nanhui Nanhua Hospital | Hepatitis B | 04/23 | 12/23 | | |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
2014-000453-37: Treatment with association of two drugs (Viread and Pegasys) in patients with hepatitis B. TRATTAMENTO CON ASSOCIAZIONE DI DUE FARMACI (VIREAD E PEGASYS) NEI PAZIENTI AFFETTI DA EPATITE B |
|
|
| Ongoing | 3 | 80 | Europe | Viread, Pegasys, Tablet, Solution for injection, Viread, Pegasys | Azienda Ospedaliera di Padova, Azienda Ospedaliera di Padova | Hepatitis B virus (HBV) EPATITE CRONICA HBV-CORRELATA, Chronic liver disease caused by hepatitis B MALATTIA EPATICA CRONICA CAUSATA DAL VIRUS DELL’EPATITE B, Diseases [C] - Virus Diseases [C02] | | | | |
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon |
|
|
| Ongoing | 3 | 50 | Europe | KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS | OSPEDALE S. RAFFAELE | patients affected by HIV and chronic HCV or compensated cirrhosis | | | | |
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ |
|
|
| Ongoing | 3 | 60 | Europe | KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS | OSPEDALE S. RAFFAELE | PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES | | | | |
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1. |
|
|
| Ongoing | 3 | 414 | Europe | Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus | Charité Universitätsmedizin Berlin | First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV | | | | |
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates |
|
|
| Ongoing | 3 | 100 | Europe | Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg | Karolinska University hospital Huddinge | Chronic hepatitis C infection | | | | |
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients. |
|
|
| Ongoing | 3 | 110 | Europe | Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus | Swedish Orphan International AB | Hepatitis C | | | | |
NCT01369212: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B |
|
|
| Completed | 3 | 201 | Canada, US | Tenofovir, Hepatitis B, Viread, Peginterferon-alfa 2a and tenofovir, PEGASYS, tenofovir | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pittsburgh, National Center for Research Resources (NCRR) | Hepatitis B | 03/21 | 03/21 | | |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
2014-003894-41: Effect of Interferon on protecting immune response in chronic hepatitis B patients under treatment for the infection with standard antiviral therapy Effetto dell’Interferone sulla risposta immunitaria proteggente in pazienti con epatite B cronica già in trattamento per l’infezione con terapia antivirale standard |
|
|
| Ongoing | 2 | 80 | Europe | Peginterferone alfa-2a, Entecavir, Tenofovir Disoproxil, Solution for injection in pre-filled syringe, Tablet, Pegasys, Baraclude, Viread | Azienda Ospedaliero-Universitaria di Parma, F. Hoffmann - La Roche Ltd, Gilead Sciences srl, Regione Emilia-Romagna | Chronic hepatitis B infection Infezione da Epatite B cronica, Chronic hepatitis B infection Infezione da Epatite B cronica, Diseases [C] - Virus Diseases [C02] | | | | |
2014-000815-15: add-on therapy of HBV chronic infection Terapia di associazione sequenziale della epatite B cronica |
|
|
| Ongoing | 2 | 40 | Europe | pegylated interferon alpha 2a, Suspension for injection in pre-filled pen, Pegasys | Azienda Ospedaliera, Polo Universitario Luigi Sacco, Milano, Università degli Studi di Milano | Chronic hepatitis B Epatite B cronica, Chronic Hepatitis B epatite B cronica, Diseases [C] - Virus Diseases [C02] | | | | |
2016-001010-17: Treatment withdrawal in patients with hepatitis B virus infection to promote clearance of the virus from the body |
|
|
| Ongoing | 2 | 240 | Europe | Peginterferon alfa-2a, Solution for injection in pre-filled syringe, Pegasys | Imperial College, London, NIHR EME | Hepatitis B viral infection, Hepatitis B viral infection, Diseases [C] - Virus Diseases [C02] | | | | |
2017-001647-12: A study to determine how safe the treatment is for subjects diagnosed with hepatitis B virus infections when combined with other treatments for hepatitis B. Subjects must have no evidence of liver damage. Un estudio para determinar la seguridad del tratamiento para los sujetos diagnosticados con infecciones por el virus de la hepatitis B cuando se combinan con otros tratamientos para la hepatitis B. Los sujetos no deben tener evidencia de daño hepático. |
|
|
| Ongoing | 2 | 20 | Europe | ARB-001467, Viread, Pegasys, ARB-001467, Solution for infusion, Film-coated tablet, Solution for injection in pre-filled syringe, Viread, Pegasys | Arbutus Biopharma Corporation, Arbutus Bipoharma Corporation | Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) Pacientes con infección crónica por el virus de la hepatitis B (HBC) HBeAg-negativo sin cirrosis, Subjects infected with hepatitis B virus Los sujetos infectados con el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02] | | | | |
2019-001485-15: This study will use an investigational product (bulevirtide) for the treatment of chronic hepatitis Delta to learn the therapeutic effect, and safety of the drug in humans. |
|
|
| Ongoing | 2 | 175 | Europe | Bulevirtide, Lyophilisate for solution for injection, Solution for injection, Pegasys | MYR GmbH, MYR GmbH | Chronic Hepatitis Delta, Chronic Hepatitis Delta, Diseases [C] - Virus Diseases [C02] | | | | |
2019-004978-26: A clinical study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide analog regimen with or without pegylated interferon alpha-2a in treatment-naïve patients with HBeAg positive chronic hepatitis B virus infection. |
|
|
| Not yet recruiting | 2 | 80 | Europe | JNJ-73763989, JNJ-56136379, Solution for injection, Tablet, Film-coated tablet, Solution for injection in pre-filled syringe, Tenofovir disoproxil Mylan 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Sciences Ireland Unlimited Company | Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02] | | | | |
2021-002450-81: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection. Estudio clínico para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética del tratamiento con JNJ-73763989, análogos de nucleos(t)ido e interferón pegilado alfa-2a en pacientes con infección crónica por el virus de la hepatitis B. |
|
|
| Ongoing | 2 | 102 | Europe | JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Entecavir Mylan 0.5 mg film-coated tablets, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research and Development LLC | Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Chronic Hepatitis B Virus Infection Infección crónica por el virus de la hepatitis B, Diseases [C] - Virus Diseases [C02] | | | | |
2021-001033-39: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR -2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection |
|
|
| Not yet recruiting | 2 | 260 | Europe | Pegasys, VIR-2218, VIR-3434, NA, Solution for injection, Lyophilisate for solution for injection, Pegasys | Vir Biotechnology, Inc., Vir Biotechnology, Inc. | Chronic HBV infection., Chronic infection of Hepatitis B Virus., Diseases [C] - Immune System Diseases [C20] | | | | |
| Recruiting | 2 | 160 | RoW | PR4 + LDV/SOF + ASV 4 wk, Pegasys®, Copegus®, Harvoni®, Sunvepra®, PR4 + LDV/SOF + SMV 4 wk, OLYSIO®, PR4 + LDV/SOF + ASV 6 wk, PR4 + LDV/SOF + SMV 6 wk, PR4 + LDV/SOF + ASV 8 wk, PR4 + LDV/SOF + SMV 8 wk, PR4 + LDV/SOF + ASV 12 wk, PR4 + LDV/SOF + SMV 12 wk | Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital of Southern Medical University | Chronic Hepatitis C Infection | 10/22 | 12/22 | | |
2020-003956-34: A Clinical Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection. |
|
|
| Not yet recruiting | 2 | 50 | Europe | JNJ-73763989, Solution for injection, Film-coated tablet, Solution for injection in pre-filled syringe, Viread 245 mg film-coated tablets, Vemlidy 25 mg film-coated tablets, Entecavir Mylan 0.5 mg film-coated tablets, Pegasys 180 micrograms solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research and Development LLC | Chronic Hepatitis B Virus Infection, Chronic Hepatitis B Virus Infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04426968: A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B |
|
|
| Completed | 2 | 96 | RoW | Hepalatide 2.1mg, L47, Hepalatide 4.2mg, Hepalatide 6.3mg, placebo 2.1mg, placebo 4.2mg, placebo 6.3mg, Pegylated Interferon, Pegasys | Shanghai HEP Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 11/23 | 11/23 | | |
NCT05244057: A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients |
|
|
| Recruiting | 2 | 30 | RoW | Hepalatide, L47, Placebo of Hepalatide, Placebo, Tenofovir Alafenamide Tablets, Vemlidy, Pegylated Interferon alfa 2a, Pegasys | Shanghai HEP Pharmaceutical Co., Ltd., Shanghai Tong Ren Hospital, Shanghai East Hospital | Chronic Hepatitis B | 08/24 | 08/24 | | |
| Active, not recruiting | 2 | 280 | Europe, Canada, US, RoW | Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531), siRNA (RO7445482), PEG-IFN, Pegasys®, PD-L1 LNA (RO7191863) | Hoffmann-La Roche | Hepatitis B, Chronic | 08/24 | 01/25 | | |
ChiCTR-OPQ-14005299: Tolerance, pharmacokinetics and pharmacodynamics of PEG-INF-alpha 2b in healthly volunteers: A Randomized, Single center, drug control, Open-Label study |
|
|
| Recruiting | 1 | 58 | | PegIntron subcutaneously ;PEGASYS subcutaneously ;hypodermic | West China Hospital, Sichuan University; West China Hospital, Sichuan University, ANHUI ANKE BIO TECNOLOGY(GROUP) CO.,LTD | Chronic hepatitis B and C | | | | |
ChiCTR-TRC-12002116: A multi-center randomized controlled clinical trial on treatment of chronic hepatitis C using Vitamin D combine pegylated interferon + ribavirin |
|
|
| Completed | N/A | 200 | | vitamin D + peg-INF-alpha-2a ;peg-INF-alpha-2a | Department of Infectious Deases of First Teaching Hospital of Xinjiang Medical University; Department of Infectious Deases of First Teaching Hospital of Xinjiang Medical University, Roche China (Shanghai) | Hepatitis C | | | | |
NCT03957629: Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis |
|
|
| Recruiting | N/A | 186 | RoW | Tenofovir Disoproxil Fumarate, Viread, Beixin, PEG-Interferon alfa 2a, Pegasys | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Liver Fibrosis | 07/21 | 07/23 | | |
| Available | N/A | | Europe, RoW | REP 2139-Mg, Tenofovir Disoproxil Fumarate, Viread, Pegylated interferon alpha2a, Pegasys | Replicor Inc. | Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis, Ascites Hepatic, Varices, Esophageal, Hepatocellular Carcinoma | | | | |
| Recruiting | N/A | 80 | Europe | Bulevirtide, Entecavir, Tenofovir, Pegasys | University of Athens | Hepatitis D | 11/23 | 12/23 | | |
NCT03771677: To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. |
|
|
| Recruiting | N/A | 400 | RoW | Nucleotide Analog, Nucleotide Analogs, Interferon Alfa-2A, Pegasys | Sun Yat-sen University, First People's Hospital of Foshan, Eighth Affiliated Hospital, Sun Yat-sen University | Hepatitis B | 12/23 | 12/24 | | |
